US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration (FDA) has approved its BrainSense Adaptive deep brain stimulation (aDBS) system and BrainSense Electrode Identifier (EI) for treating Parkinson’s disease (PD). The approval marks a milestone in personalized neurological therapies.
Technology Highlights
The BrainSense system uses adaptive technology to enhance traditional DBS by detecting, classifying, and responding to real-time brain signals. Key features include:
- Adaptive Stimulation: Automatically adjusts therapy based on patient-specific neural activity.
- Signal Classification: Identifies different brain signals to tailor treatment.
- Personalized Care: Provides precise, customized therapy to improve patient outcomes.
Clinical Impact
DBS delivers electrical impulses to brain regions affected by PD via an implanted neurostimulator. BrainSense’s real-time adjustments aim to optimize efficacy and reduce side effects, addressing unmet needs in PD management.-Fineline Info & Tech
Leave a Reply